Gritstone Bio (GRTS)
GRTS
Oncology
BiotechSign Signal Grade
F
Signal Grade
1.2/100 composite signal score
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Insider Buying
0
Publications
100
Clinical Activity
0
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
0
Clinical Trials
(ClinicalTrials.gov aggregate)
(ClinicalTrials.gov aggregate)
5
PubMed Publications
0
Catalyst Records
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Recent News & SEC Filings
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer. — J Immunother Cancer 2026 Aug 26 PMID 42648750
- Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. — Lancet Oncol 2026 Sep PMID 42636833
- Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. — Nat Med 2026 Aug PMID 42581230
- Vobramitamab duocarmazine, an anti-B7-H3 antibody-drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion. — Cancer 2026 Aug 1 PMID 42487497
- Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies. — J Immunother Cancer 2026 Jul 20 PMID 42476725
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Gritstone Bio.
Full GRTS Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.